Hecht Beth

See RemarksXeris Biopharma Holdings, Inc. (XERS) · full profile →Form 4 · filed Feb 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$124K
Net Open-Market Flow
-$124K
Transactions
6
5 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2026Sell(S)17K$7.45$124K1.2M
Jan 31, 2026Tax withholding(F)47K$7.36$345K1.3M
Jan 31, 2026Tax withholding(F)24K$7.36$179K1.3M
Jan 31, 2026Tax withholding(F)98K$7.36$724K1.3M
Jan 30, 2026Grant(A)121K$01.4M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 30, 2026Grant(A)162K$0162K

Transaction Codes

S
Open-market sale
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001652410-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly: